Table 3.
Outcomes in patients with COVID-19-associated TMA in relation to received therapy.
| Patients with TTP | FFP | TPE + Steroid | TPE ± Steroid + Caplacizumab | TPE ± Steroid + Rituximab | TPE + Steroid + Rituximab + Caplacizumab |
|---|---|---|---|---|---|
| N = 18 | 2 | 5 + 1 * | 3 | 5 | 2 |
| Recovered | 1 | 5 | 3 | 4 | 2 |
| Died | 1 | 1 | 1 | ||
| Patients with aHUS | TPE or FFP only | Steroid only | TPE + steroid only | Eculizumab or ravolizumab |
No specific therapy or else |
| N = 28 | 5 | 1 | 1 | 16 * 12 also TPE ± steroid |
5 |
| Recovery of renal function | |||||
| Complete | 1 | 5 | 2 | ||
| Partial/unknown magnitude | 3 | 1 | 1 | 5 | |
| ESRD | 1 | 4 | 2 | ||
| Died | 2 | 1 | |||
* Preterm delivery induced, did not receive steroid. Legend: aHUS, atypical hemolytic uremic syndrome; ESRD, end-stage renal disease; FFP, fresh frozen plasma; TPE, therapeutic plasma exchange; TTP, thrombotic thrombocytopenic purpura.